BR9802482A - Derivados de 5h-tiazolo[3,2-a]pirimidina. - Google Patents
Derivados de 5h-tiazolo[3,2-a]pirimidina.Info
- Publication number
- BR9802482A BR9802482A BR9802482-5A BR9802482A BR9802482A BR 9802482 A BR9802482 A BR 9802482A BR 9802482 A BR9802482 A BR 9802482A BR 9802482 A BR9802482 A BR 9802482A
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- lower alkyl
- injuries
- caused
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
- C07D239/40—One sulfur atom as doubly bound sulfur atom or as unsubstituted mercapto radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Patente de Invenção: <B>"DERIVADOS DE 5H-TIAZOLO[3,2-a]PIRIMIDINA"<D>. A invenção refere-se a compostos de fórmula geral: na qual: R^ 1^ representa hidrogênio, alquila inferior, fenila ou benzila, R^ 2^ representa alquila inferior, alcóxi inferior, -O(CH~ 2~)~ n~N(R^ 13^)(R^ 14^), -(CH~ 2~)~ n~N(R^ 13^)(R^ 14^) ou -N(R^ 15^)(CH~ 2~)~ n~N(R^ 13^)(R^ 14^), R^ 3^-R^ 12^ representam hidrogênio, halogênio, trifluoro metila, alquila inferior, cicloalquila, alcóxi inferior, hidróxi, nitro, ciano, -N(R^ 13^)~ 2~, fenila, fenilóxi, benzila ou benzilóxi, ou R^ 6^ e R^ 7^ representam em conjunto um anel benzeno, R^ 13^-R^ 15^ representam hidrogênio, alquila inferior ou cicloalquila, e n representa 1-5, bem como os seus sais farmaceuticamente aceitáveis. Esses compostos são adequados para o controle ou a prevenção de afecções neurológicas agudas e/ou crónicas, tais como a função cerebral limitada causada por operações de desvio ou transplantes, um débil suprimento de sangue ao cérebro, ferimentos no cordão espinhal, ferimentos na cabeça, hipoxia causada por gravidez, parada cardíaca, hipoglicemia, doença de Alzheimer, coréia de Hintington, ELA (esclerose lateral amiotrópica), demência causada pela AIDS, ferimentos nos olhos, retinopatia, distúrbios de cognição, doença de Parkinson idiopática ou doença de Parkinson causada por medicamentos, bem como as condições que levam a funções de deficiência de glutamato tais como, por exemplo, espasmos nos músculos, convulsões, enxaqueca, incontinência urinária, dependência de nicotina, psicoses, dependências de narcóticos, ansiedade, vómitos, dor crónica, disquinésia e depressões.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97112324 | 1997-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9802482A true BR9802482A (pt) | 2000-03-14 |
Family
ID=8227080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9802482-5A BR9802482A (pt) | 1997-07-18 | 1998-07-16 | Derivados de 5h-tiazolo[3,2-a]pirimidina. |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US5958931A (pt) |
| EP (1) | EP0891978B1 (pt) |
| JP (1) | JP3100573B2 (pt) |
| KR (1) | KR100296837B1 (pt) |
| CN (1) | CN1102596C (pt) |
| AR (1) | AR016129A1 (pt) |
| AT (1) | ATE214704T1 (pt) |
| AU (1) | AU738207B2 (pt) |
| BR (1) | BR9802482A (pt) |
| CA (1) | CA2243234C (pt) |
| CO (1) | CO5210884A1 (pt) |
| CZ (1) | CZ288944B6 (pt) |
| DE (1) | DE69804273T2 (pt) |
| DK (1) | DK0891978T3 (pt) |
| ES (1) | ES2172840T3 (pt) |
| HK (1) | HK1018439A1 (pt) |
| HR (1) | HRP980398B1 (pt) |
| HU (1) | HUP9801587A3 (pt) |
| ID (1) | ID21824A (pt) |
| IL (1) | IL125358A (pt) |
| MA (1) | MA26520A1 (pt) |
| NO (1) | NO310512B1 (pt) |
| NZ (1) | NZ330988A (pt) |
| PE (1) | PE97499A1 (pt) |
| PL (1) | PL190218B1 (pt) |
| PT (1) | PT891978E (pt) |
| RU (1) | RU2197493C2 (pt) |
| SI (1) | SI0891978T1 (pt) |
| TR (1) | TR199801367A2 (pt) |
| TW (1) | TW523518B (pt) |
| UY (1) | UY25095A1 (pt) |
| YU (1) | YU29798A (pt) |
| ZA (1) | ZA986250B (pt) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1074549B1 (en) * | 1999-08-06 | 2003-11-19 | F. Hoffmann-La Roche Ag | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors |
| CA2438582C (en) * | 2001-01-31 | 2012-06-26 | Synaptic Pharmaceutical Corporation | Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| WO2002102807A1 (fr) * | 2001-06-14 | 2002-12-27 | Banyu Pharmaceutical Co., Ltd. | Nouveaux derives d'isoxazolopyridone et leur utilisation |
| US7329662B2 (en) * | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
| RU2378277C2 (ru) * | 2004-06-21 | 2010-01-10 | Ф. Хоффманн-Ля Рош Аг | Производные пиразолпиримидина |
| KR100847160B1 (ko) * | 2004-06-21 | 2008-07-17 | 에프. 호프만-라 로슈 아게 | 피라졸로 피리미딘 유도체 |
| ES2365406T3 (es) | 2005-02-11 | 2011-10-04 | F. Hoffmann-La Roche Ag | Derivados de pirazolo-pirimidina como antagonistas de mglur2. |
| MX2007011483A (es) | 2005-03-23 | 2007-10-12 | Hoffmann La Roche | Derivados de acetilenil-pirazolo-pirimidina como antagonistas de glutamato metabotropico 2. |
| CA2623721C (en) | 2005-09-27 | 2014-05-13 | F. Hoffmann-La Roche Ag | Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| EA019085B1 (ru) | 2007-09-14 | 2014-01-30 | Янссен Фармасьютикалз, Инк. | 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны |
| EP2205565B1 (en) * | 2007-09-14 | 2013-04-17 | Janssen Pharmaceuticals, Inc. | 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones |
| NZ584145A (en) | 2007-09-14 | 2012-03-30 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones |
| MX2010005110A (es) * | 2007-11-14 | 2010-09-09 | Ortho Mcneil Janssen Pharm | Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2. |
| ES2439291T3 (es) | 2008-09-02 | 2014-01-22 | Janssen Pharmaceuticals, Inc. | Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos |
| US8697689B2 (en) | 2008-10-16 | 2014-04-15 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| MX2011005242A (es) | 2008-11-28 | 2011-09-06 | Ortho Mcneil Janssen Pharm | Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos. |
| CN101503414B (zh) * | 2009-03-04 | 2013-10-30 | 沈阳药科大学 | 噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用 |
| MY161325A (en) | 2009-05-12 | 2017-04-14 | Janssen Pharmaceuticals Inc | 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CA2760259C (en) | 2009-05-12 | 2018-05-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| ES2536433T3 (es) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| JP5852664B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| CN103298809B (zh) | 2010-11-08 | 2016-08-31 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| CA2926830C (en) * | 2013-10-11 | 2023-08-01 | F. Hoffmann-La Roche Ag | Thiazolopyrimidinones as modulators of nmda receptor activity |
| ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena |
| WO2015110435A1 (en) | 2014-01-21 | 2015-07-30 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| AU2018241628B2 (en) * | 2017-03-31 | 2022-03-17 | Basf Se | Pyrimidinium compounds and their mixtures for combating animal pests |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3660418A (en) * | 1970-03-16 | 1972-05-02 | Sandoz Ag | Certain 2 3 5 6-tetrahydroimidazo(2 1-b)thiazoles |
| EP0524055A1 (fr) * | 1991-07-19 | 1993-01-20 | Synthelabo | Dérivés d'imidazo[2,1-b]benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique |
| PL182285B1 (pl) * | 1994-08-12 | 2001-12-31 | Lilly Co Eli | Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL |
| GB9609976D0 (en) * | 1996-05-13 | 1996-07-17 | Lilly Industries Ltd | Pharmaceutical compounds |
| WO1998006724A1 (fr) * | 1996-08-09 | 1998-02-19 | Yamanouchi Pharmaceutical Co., Ltd. | Agonistes du recepteur du glutamate metabotropique |
-
1998
- 1998-07-11 EP EP98112915A patent/EP0891978B1/en not_active Expired - Lifetime
- 1998-07-11 SI SI9830130T patent/SI0891978T1/xx unknown
- 1998-07-11 DK DK98112915T patent/DK0891978T3/da active
- 1998-07-11 ES ES98112915T patent/ES2172840T3/es not_active Expired - Lifetime
- 1998-07-11 PT PT98112915T patent/PT891978E/pt unknown
- 1998-07-11 DE DE69804273T patent/DE69804273T2/de not_active Expired - Fee Related
- 1998-07-11 AT AT98112915T patent/ATE214704T1/de not_active IP Right Cessation
- 1998-07-14 NZ NZ330988A patent/NZ330988A/xx unknown
- 1998-07-14 ZA ZA986250A patent/ZA986250B/xx unknown
- 1998-07-14 NO NO19983244A patent/NO310512B1/no not_active IP Right Cessation
- 1998-07-14 ID IDP981000A patent/ID21824A/id unknown
- 1998-07-14 TR TR1998/01367A patent/TR199801367A2/xx unknown
- 1998-07-14 MA MA25167A patent/MA26520A1/fr unknown
- 1998-07-14 US US09/115,191 patent/US5958931A/en not_active Expired - Fee Related
- 1998-07-15 PE PE1998000625A patent/PE97499A1/es not_active Application Discontinuation
- 1998-07-15 JP JP10199363A patent/JP3100573B2/ja not_active Expired - Fee Related
- 1998-07-15 HU HU9801587A patent/HUP9801587A3/hu unknown
- 1998-07-15 CN CN98116063A patent/CN1102596C/zh not_active Expired - Fee Related
- 1998-07-15 YU YU29798A patent/YU29798A/sh unknown
- 1998-07-15 CA CA002243234A patent/CA2243234C/en not_active Expired - Fee Related
- 1998-07-15 IL IL12535898A patent/IL125358A/en not_active IP Right Cessation
- 1998-07-16 BR BR9802482-5A patent/BR9802482A/pt not_active Application Discontinuation
- 1998-07-16 CO CO98040510A patent/CO5210884A1/es not_active Application Discontinuation
- 1998-07-16 KR KR1019980028788A patent/KR100296837B1/ko not_active IP Right Cessation
- 1998-07-16 AR ARP980103469A patent/AR016129A1/es not_active Application Discontinuation
- 1998-07-16 PL PL98327532A patent/PL190218B1/pl unknown
- 1998-07-16 HR HR980398A patent/HRP980398B1/xx not_active IP Right Cessation
- 1998-07-16 CZ CZ19982239A patent/CZ288944B6/cs not_active IP Right Cessation
- 1998-07-16 UY UY25095A patent/UY25095A1/es unknown
- 1998-07-17 AU AU77302/98A patent/AU738207B2/en not_active Ceased
- 1998-07-17 RU RU98114683/04A patent/RU2197493C2/ru not_active IP Right Cessation
- 1998-07-21 TW TW087111834A patent/TW523518B/zh not_active IP Right Cessation
-
1999
- 1999-07-14 HK HK99103032A patent/HK1018439A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9802482A (pt) | Derivados de 5h-tiazolo[3,2-a]pirimidina. | |
| MY126586A (en) | Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands | |
| ES2420860T3 (es) | Compuestos amino-heterocíclicos usados como inhibidores de la PDE9 | |
| DE69820866D1 (de) | [1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-DERIVATE | |
| PT1052246E (pt) | Derivados de amino-acidos contendo fluor | |
| PE20001467A1 (es) | Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina | |
| CY1107401T1 (el) | Παραγωγα βενζοθειαζολιου πα την θεραπευτικη αντιμετωπιση της νοσου alzheimer και της νοσου parkinson | |
| MXPA02011373A (es) | Derivados de triazol. | |
| BR0317483A (pt) | Derivados de benzodiazepina para o tratamento de desordens neurológicas | |
| RU98114683A (ru) | Производные 5-н-тиазол[3,2-a]пиримидина | |
| HK1080456A1 (en) | N-substituted hydromorphones and the use thereof | |
| HK1013816A1 (en) | 1-Piperazino-1,2-dihydroindene derivatives | |
| MX2007004639A (es) | Derivados de imidazo-benzodiazepina. | |
| MXPA04000278A (es) | Uso de antagonistas del receptor nk-1 con estructura piridinica para tratamiento de lesiones cerebrales, espinales o neuronales. | |
| ATE325610T1 (de) | Xanthinderivative zur behandlung von hirnischämie | |
| BR9902651A (pt) | Derivados de diaza-espiro[3,5]nonano | |
| ATE284684T1 (de) | Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut | |
| EP1123703A4 (en) | IMMUNOMODULATOR DRUG COMPOSITION | |
| US20050107360A1 (en) | Bicyclic compounds | |
| BR0110874A (pt) | Derivados de sulfonamida | |
| JO2236B1 (en) | Carbamic acid derivatives | |
| ECSP982597A (es) | DERIVADOS DE 5H-TIAZOLO (3,2,a) PIRIMIDINA | |
| EP0919233B8 (en) | Therapeutic agent for kidney diseases | |
| ECSP003717A (es) | Derivados de benzodiazepin | |
| MX9705390A (es) | Uso de los 3,4-difenil-cromanos para la fabricacion de una composicion farmaceutica para el tratamiento o profilaxis de desordenes degenerativos cerebrales. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |